**PRODUCT DATA**

**Product name(s):** Cytokeratin 19, mouse mAb (clone BA17)

<table>
<thead>
<tr>
<th>Catalogue number:</th>
<th>CB 10198</th>
<th>Batch number:</th>
<th>Expiry date:</th>
</tr>
</thead>
</table>

**Introduction:**

Cytokeratins comprise the fibrillar intra-cytoplasmic matrix of epithelial cells. The combination of the various cytokeratins, as detected by the use of specific antibodies, is often indicative of cellular origin. The distribution of the individual cytokeratin types within tumours derived from epithelial cells has been used to sustain differential diagnosis.

Cytokeratin 19 is a small (variably reported from 40-44kDa), acidic (type I) cytokeratin which lacks the C-terminal non-α-helical tail domain, found in other cytokeratins. Cytokeratin 19 is found in a wide range of epithelial tissues, appearing as a major component in many simple epithelia, and usually as a minor component in diverse stratified epithelia. This cytokeratin has been found in many tumours of epithelial origin, with the notable exception of hepatocellular carcinomas. The detection of cytokeratin 19 in human skin, breast tissue and derivative tumours using antibody BA17 has been documented.

**Product information:**

Hybridoma (clone BA17) secreting the antibody to human cytokeratin 19 was generated by immunising mice with detergent-insoluble extracts of human reduction mammoplasty epithelial organoids. The antibody is an IgG1. The antibody (designated 194) was included in the 1998 ISOBM TD5-1 workshop report.

Application data

This antibody has been used to immunostain cytokeratin 19 in a wide range of epithelial cells and associated malignancies. For immunocytochemistry the use of para-formaldehyde-fixed frozen cryostat or de-waxed tissue sections is recommended. A dilution of 1:100 or greater is recommended for both Western blotting and immunohistochemistry when incubation in primary antibody is carried on overnight at 4°C. Antigen retrieval procedures, including enzyme digestion, may enhance reaction product deposition. Some cross-reactivity with cytokeratin 8 (a.a. 340-365; peptide CK8:2) has been reported.

NOTES: Optimal dilutions must be determined by experimentation. *Indirect immunoperoxidase procedure with detection using ECL procedure (Amersham International plc), exposure for 1min. **When used in conjunction with sensitive detection reagents, such as ABC-peroxidase (Vector-Elite) or the PAP technique.

**Vial contents, Storage and Use:**

See vial label for volume. Vial contains a purified immunoglobulin fraction (at 1mg/mL) prepared from tissue culture supernatant by protein A affinity chromatography. The solution contains 0.1% sodium azide and 1% bovine serum albumin. Dilute to working strength with phosphate-buffered saline (PBS) containing 0.1% w/v sodium azide.

Store unopened vial at -20°C until required for use. AVOID REPEATED FREEZE-THAW CYCLES. Aliquot undiluted antibody into smaller volumes prior to freezing if appropriate. Store diluted antibody at 2-4°C and use within 1 month.

**References:**